Digi.Bio harnesses the power of Digital Microfluidics to rapidly and precisely manipulate droplets on a microscale. This technology is based on electrowetting (EWOD), a technique of microfluidics which allows control of fluid flow and shape using electrical signals applied over a planar electrode array.

Madam Therapeutics, in collaboration with the LUMC and AMC, is developing antibiotics with a new mechanism of action to contribute to the increasing issue of antimicrobial resistance to traditional antibiotics. The lead compound SAAP-148 is currently being developed for the treatment of for example wound infections and is nearing the end of the pre-clinical fase. The first clinical study is expected to kick-off end of 2019. Madam would in the near future also like to develop other SAAPs for (semi-) systemic infections. 

How do you assess whether the performance of transplantation surgeons is “good enough”? And how do you do so fairly, without penalizing doctors for treating patients who are especially at risk? I’ll discuss the LUMC’s initiative to use Cumulative Sum charts to monitor surgeon performance.How do you assess whether the performance of transplantation surgeons is “good enough”? And how do you do so fairly, without penalizing doctors for treating patients who are especially at risk? I’ll discuss the LUMC’s initiative to use Cumulative Sum charts to monitor surgeon performance.